Target RWE Presenting at ISPE 2025: Powering Evidence Generation with Causal Inference

Company will showcase scientific leadership with three key presentations and highlights scalable, data-agnostic research solutions at ISPE Annual Conference 2025.

DURHAM, N.C., Aug. 21, 2025 /PRNewswire/ -- Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced its featured presentations and research insights at the International Society for Pharmacoepidemiology (ISPE) 2025 Annual Conference in Washington, DC.

With a strong emphasis on causal inference and data-agnostic methods, Target RWE continues to drive innovation in observational research—providing life sciences partners with powerful tools to design, execute, and interpret studies that meet modern evidentiary demands.

Leading with Causal Inference at ISPE

Target RWE will present three abstracts at ISPE 2025, each reflecting the company's commitment to methodological rigor and real-world impact:

Symposium Presentation
Integrating Real-World Data with Randomized Controlled Trials: Advancing Evidence Generation
Jennifer Christian, PharmD, PhD, FISPE — Chief Scientific Officer, Target RWE

This workshop will explore practical strategies for integrating Real-World Data (RWD) with Randomized Controlled Trials (RCTs) to strengthen evidence generation for regulatory, clinical, and research applications. With presentations from international experts and case studies spanning oncology and cardiovascular interventions, attendees will learn methods for designing external control arms, ensuring relevance and reliability of data integration, and extending trial results to broader patient populations.

Poster Presentations

Estimating Artificial Censoring Weights for Clone Censor Weighting Studies: Techniques and Lessons Learned
David Pritchard, PhD — Director, Data Management & Statistics

This presentation will focus on practical strategies for implementing clone censor weighting (CCW), a method used to estimate counterfactual outcomes under treatment protocols while addressing challenges such as immortal time bias. Emphasis will be placed on estimating artificial censoring weights—crucial for appropriately reweighting adherent patients.

Power vs. Precision When Estimating Risk Differences Using Observational Data: A Case Study from TARGET-IBD
Yasmmyn Salinas, PhD, MPH — Clinical Epidemiologist

This presentation explores the challenges of applying traditional power-based sample size approaches to real-world observational studies, where sample sizes are fixed and confounding is present. Using data from Target RWE's IBD cohort, the study compares power and precision estimates for assessing the risk difference in surgery or hospitalization among patients who achieved early versus late disease remission.

These contributions demonstrate Target RWE's ability to close evidence gaps and apply advanced analytics to complex treatment and policy questions. From designing nuanced treatment decision studies to generating high-quality insights, the company continues to lead in the use of real-world data for pharmacoepidemiologic research.

A Trusted, Data-Agnostic Research Partner

At Target RWE, causal inference isn't just a buzzword—it's a core scientific strength driven by our in-house team of experienced epidemiologists and statisticians. These experts work side-by-side with clinical research teams to make complex methodologies more actionable and accessible, translating advanced techniques into meaningful insights that inform decision-making across the drug development lifecycle.

This same team helped develop causalStudio™, our proprietary platform designed to simplify and scale the application of causal inference. Built for real-world use, causalStudio™ enables researchers to simulate trial-like conditions, align on clear estimands, and generate reliable, defensible outputs that stand up to regulatory and scientific scrutiny.

Supported by our data-agnostic infrastructure and custom analytics consulting, Target RWE delivers flexible, high-impact evidence generation—empowering clients to tackle high-stakes questions with confidence and clarity.

Shaping the Future of Pharmacoepidemiology

"Target RWE is committed to helping our partners generate high-quality, real-world evidence—whether for regulatory filings, health technology assessments, or scientific publication," said Jennifer Christian, PharmD, PhD, FISPE, Chief Scientific Officer at Target RWE. "I am excited to see our strong presence at ISPE this year, reflecting our dedication to collaboration, innovation, and scientific excellence."

As pharmacoepidemiology continues to intersect with regulatory science, Target RWE remains at the forefront—offering not just data, but direction.

To learn more about Target RWE's custom analytics, causal inference capabilities/demo, and collaborative research services, visit www.targetrwe.com or contact [email protected].

SOURCE Target RWE